Scorpion Therapeutics Stock
Scorpion Therapeutics is a precision oncology company that broadens the reach and impact of precision medicine for cancer patients.
Sign up today and learn more about Scorpion Therapeutics Stock
Invest in or value your shares in one or many pre-IPO companies through an EquityZen investment vehicle.
About Scorpion Therapeutics Stock
Scorpion Therapeutics was founded to broaden the reach and impact of precision medicine to more people with cancer. The company is integrating cutting-edge technologies across target discovery, medicinal chemistry, and translational medicine to deliver Precision Oncology 2.0. Scorpion’s experienced leadership team is executing a fit-to-purpose model to efficiently unlock the next generation of precision oncology.
Funding History
October 2020 | $108M |
---|---|
January 2021 | $162M |
Management
Founder
Gaddy Getz
Interim Chief Executive Officer
Adam Friedman
Co-Founder & Board Member
Keith Flaherty
Chief Financial Officer
Brian Piper
Founder
Liron Bar-Peled
Board Observer
Paulina Hill
Press
businesswire - Feb, 12 2024
Scorpion Therapeutics Appoints Precision Medicine Leader Jeff Albers as Strategic Advisorbioprocessintl - Feb, 12 2024
Ins & Outs: C-suite changes across biotechs - BioProcess Insiderbusinesswire - Jan, 4 2024
Scorpion Therapeutics Appoints Adam Friedman, M.D., Ph.D., as Chief Executive Officer and Expands Leadership Teambusinesswire - Oct, 13 2023
Scorpion Therapeutics Presents Preclinical Data for STX-241, abioworld - Oct, 8 2023
Scorpion Therapeutics patents new EGFR and HER2 inhibitors for cancer